XDH and metabolic dysfunction-associated steatotic liver disease: Additionally, xanthine oxidase inhibition has been closely related with diminution in uric acid levels and attenuation of fat accumulation in liver cells [35]; thus, xanthine oxidase inhibitors could be considered as putative therapies against MASLD development, especially when hyperuricemia appears [36].